Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 6/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL441272 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL438999 | 0.84 | KDM4E (0.54) | KMT2AKDM4EALDH1A1GAACYP2C19 | |
| SCHEMBL438998 | 0.84 | KDM4E (0.54) | KMT2AKDM4EALDH1A1GAACYP2C19 | |
| SCHEMBL25247992 | 0.80 | KMT2A (0.56) | SMN1; SMN2KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL5361880 | 0.77 | HDAC1 (0.74) | SMN1; SMN2KMT2AALDH1A1GAACYP3A4 | |
| SCHEMBL443394 | 0.76 | KDM4E (0.49) | SMN1; SMN2KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL3110634 | 0.76 | ALDH1A1 (0.51) | SMN1; SMN2KMT2AALDH1A1GAACYP1A2 | |
| SCHEMBL29988236 | 0.76 | CYP3A4 (0.56) | SMN1; SMN2KMT2AKDM4EALDH1A1CYP3A4 | |
| SCHEMBL3110639 | 0.76 | ALDH1A1 (0.51) | SMN1; SMN2KMT2AALDH1A1GAACYP1A2 | |
| SCHEMBL443393 | 0.76 | KDM4E (0.49) | SMN1; SMN2KMT2AKDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | SMN1; SMN2 2301/4885KMT2A 667/4885KDM4E 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.